A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma (KEYNOTE-224)
The purpose of this study is to evaluate the safety and tolerability of the study drug, Pembrolizumab, in patients with advanced hepatocellular carcinoma (HCC).
Advanced Liver Cancer (Hepatocellular Carcinoma)
≥ 18 years of age
Liver Cancer (BCLC) Stage C or B
18 - 100
Healthy Volunteers Needed
Duration of Participation
You will receive the study drug (Pembrolizumab) until your disease progresses, you can’t tolerate the treatment, or you and/or your doctor decide to stop treatment.
After you finish treatment your doctor will continue to watch you for side effects and follow your condition until study completion.
OHSU Knight Cancer Institute Information line 503-494-1080
Merck Sharp & Dohme Corp., (a subsidiary of Merck & Co. Inc.)